

Hepeng Jia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1764012/publications.pdf>

Version: 2024-02-01

65
papers

714
citations

758635

12
h-index

580395

25
g-index

67
all docs

67
docs citations

67
times ranked

735
citing authors

#	ARTICLE	IF	CITATIONS
1	I Wear a Mask for My Country: Conspiracy Theories, Nationalism, and Intention to Adopt Covid-19 Prevention Behaviors at the Later Stage of Pandemic Control in China. <i>Health Communication</i> , 2023, 38, 543-551.	1.8	21
2	When scientific literacy meets nationalism: Exploring the underlying factors in the Chinese public's belief in COVID-19 conspiracy theories. <i>Chinese Journal of Communication</i> , 2022, 15, 227-249.	1.3	13
3	More engagement but less participation: China's alternative approach to public communication of science and technology. <i>Public Understanding of Science</i> , 2022, 31, 331-339.	1.6	3
4	Is It All a Conspiracy? Conspiracy Theories and People's Attitude to COVID-19 Vaccination. <i>Vaccines</i> , 2021, 9, 1051.	2.1	40
5	Passport to a Mighty Nation: Exploring Sociocultural Foundation of Chinese Public's Attitude to COVID-19 Vaccine Certificates. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10439.	1.2	16
6	China targets single-use plastics. <i>C&EN Global Enterprise</i> , 2020, 98, 13-13.	0.0	0
7	Conveyor belt structure of belt dryer: Analysis and optimization. <i>Engineering Failure Analysis</i> , 2020, 115, 104686.	1.8	3
8	Diagnosing COVID-19. <i>C&EN Global Enterprise</i> , 2020, 98, 5-5.	0.0	0
9	Chinese agchem giant set to emerge. <i>C&EN Global Enterprise</i> , 2020, 98, 11-11.	0.0	0
10	Air pollution levels linked to stroke risk. <i>C&EN Global Enterprise</i> , 2020, 98, 9-9.	0.0	0
11	Visibility challenges for Asian scientists. <i>Nature Reviews Physics</i> , 2020, 2, 178-180.	11.9	1
12	Chinese academics who work abroad are slower to win major honour. <i>Nature</i> , 2020, 577, 302-303.	13.7	0
13	Agriculture: science and technology safeguard sustainability. <i>National Science Review</i> , 2019, 6, 595-600.	4.6	12
14	China strengthens its campaign against scientific misconduct. <i>C&EN Global Enterprise</i> , 2019, 97, 29-29.	0.0	0
15	Paleontology: advancing China's international leadership. <i>National Science Review</i> , 2019, 6, 171-176.	4.6	1
16	Passive communicators: Chinese scientists' interaction with the media. <i>Science Bulletin</i> , 2018, 63, 402-404.	4.3	3
17	China reshuffles science governance. <i>C&EN Global Enterprise</i> , 2018, 96, 17-17.	0.0	0
18	Discovery central. <i>Nature</i> , 2018, 563, S16-S17.	13.7	0

#	ARTICLE	IF	CITATIONS
19	Strong spending compounds chemistry prowess. Nature, 2018, 564, S68-S69.	13.7	1
20	Yielding results to feed a people. Nature, 2018, 564, S62-S63.	13.7	1
21	How to find a job in China. Nature, 2018, 553, S4-S7.	13.7	1
22	Core values. Nature, 2018, 558, S14-S15.	13.7	0
23	Who will win the future of display technologies?. National Science Review, 2018, 5, 427-431.	4.6	26
24	Keeping a lid on open science. Nature, 2017, 545, S62-S64.	13.7	3
25	Encountered but Not Engaged: Examining the Use of Social Media for Science Communication by Chinese Scientists. Science Communication, 2017, 39, 646-672.	1.8	26
26	A league of their own. Nature, 2017, 550, S186-S187.	13.7	0
27	Neighbours in knowledge. Nature, 2017, 550, S188-S191.	13.7	0
28	Road to international publications: an empirical study of Chinese communication scholars. Asian Journal of Communication, 2017, 27, 172-192.	0.6	4
29	Scientific collaborations shine on Belt and Road. National Science Review, 2017, 4, 652-657.	4.6	12
30	We have confidence to lead gravitational-wave science: an interview with Yueliang Wu. National Science Review, 2017, 4, 718-720.	4.6	0
31	Using science to conquer haze: an interview with Tong Zhu. National Science Review, 2017, 4, 867-869.	4.6	0
32	Alliances for scientific success. Nature, 2015, 528, S187-S189.	13.7	0
33	China's watchdog clamps down on genome sequencing services. Nature Biotechnology, 2014, 32, 511-511.	9.4	1
34	Unbalanced progress: The hard road from science popularisation to public engagement with science in China. Public Understanding of Science, 2014, 23, 32-37.	1.6	45
35	China clampdown on GSK linked to drug costs. Nature Biotechnology, 2013, 31, 861-861.	9.4	0
36	China overhauls drug regulation agency. Nature Biotechnology, 2013, 31, 375-375.	9.4	1

#	ARTICLE	IF	CITATIONS
37	GM phobia spreads in South Asia. Nature Biotechnology, 2012, 30, 1017-1018.	9.4	17
38	Newsmaker: Biocentury Transgene. Nature Biotechnology, 2011, 29, 12-12.	9.4	3
39	China's new WHO flu monitoring center seeks to reverse criticism. Nature Medicine, 2011, 17, 520-520.	15.2	1
40	Chinese biotechs wrestle with transparency, cultural hurdles. Nature Biotechnology, 2011, 29, 377-378.	9.4	0
41	Chinese vaccine developers gain WHO imprimatur. Nature Biotechnology, 2011, 29, 471-472.	9.4	5
42	Chinese green light for GM rice and maize prompts outcry. Nature Biotechnology, 2010, 28, 390-391.	9.4	22
43	China's heparin billionaires. Nature Biotechnology, 2010, 28, 637-637.	9.4	1
44	China tightens IP protection, but concerns linger. Nature Biotechnology, 2009, 27, 787-788.	9.4	3
45	Regulators scramble to tighten loopholes after heparin debacle. Nature Biotechnology, 2008, 26, 477-478.	9.4	4
46	RESEARCH FACILITIES: China Supersizes Its Science. Science, 2007, 315, 1354-1356.	6.0	4
47	China syndrome—a regulatory framework in meltdown?. Nature Biotechnology, 2007, 25, 835-837.	9.4	8
48	Chinese manufacturers vie for piece of outsourcing pie. Nature Biotechnology, 2007, 25, 1337-1338.	9.4	7
49	Chinese biotech hamstrung by production issues. Nature Biotechnology, 2007, 25, 147-148.	9.4	11
50	Poor enforcement could jeopardize China's drug innovation policy. Nature Biotechnology, 2006, 24, 1182-1183.	9.4	1
51	Gene therapy finds welcoming environment in China. Nature Medicine, 2006, 12, 263-264.	15.2	13
52	Frequent cases force China to face up to scientific fraud. Nature Medicine, 2006, 12, 867-867.	15.2	10
53	Controversial Chinese gene-therapy drug entering unfamiliar territory. Nature Reviews Drug Discovery, 2006, 5, 269-270.	21.5	17
54	Lack of private financing hobbles emerging biotech regions. Nature Biotechnology, 2006, 24, 7-9.	9.4	3

#	ARTICLE	IF	CITATIONS
55	China offers alternative gateway for experimental drugs. Nature Biotechnology, 2006, 24, 117-118.	9.4	57
56	China kickstarts its vaccine market. Nature Biotechnology, 2006, 24, 375-375.	9.4	1
57	China beckons to clinical trial sponsors. Nature Biotechnology, 2005, 23, 768-768.	9.4	13
58	China steps towards international M&A. Nature Biotechnology, 2005, 23, 159-159.	9.4	2
59	China ramps up efforts to commercialize GM rice. Nature Biotechnology, 2004, 22, 642-642.	9.4	25
60	China moves to reform biotech policies. Nature Biotechnology, 2004, 22, 1197-1197.	9.4	4
61	China approves first gene therapy. Nature Biotechnology, 2004, 22, 3-4.	9.4	224
62	China pushes liver proteomics. Nature Biotechnology, 2004, 22, 136-136.	9.4	9
63	IP litigation in China could drive innovation. Nature Biotechnology, 2004, 22, 368-368.	9.4	5
64	GM labeling in China beset by problems. Nature Biotechnology, 2003, 21, 835-836.	9.4	7
65	Biotech parks proliferate, despite concerns over sustainability. Nature Biotechnology, 2003, 21, 1259-1260.	9.4	3